Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media

Kyung Jin Min, Kyeong A. So, Jieun Lee, Hye Ri Hong, Jin-Hwa Hong, Jae Kwan Lee, Aeree Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To validate the efficacy of Seeplex HPV4A ACE for the detection of high-risk (HR) human papillomavirus (HPV) and HPV 16 and/or HPV 18 genotypes as compared to the PCR method and the Cervista HPV assays in cervical swab samples. Methods: Besides liquid-based cytology, additional 97 cervical swab samples were collected for HPV genotyping by HPV4A ACE, Cervista HPV assays, and PCR method. To check the statistical differences, we also conducted the paired proportion test, Cohen' s κ statistic, and a receiver operating characteristic curve. Results: Seeplex HPV4A ACE and the Cervista HPV HR showed substantial agreement with PCR for detection of HR HPVs (88.3%, κ=0.767 and 81.7%, κ=0.636, respectively). Seeplex HPV4A ACE also showed substantial agreement with the Cervista HPV 16/18 test (89.5%, κ=0.628). Additionally, the sensitivity and specificity of Seeplex HPV4A ACE and Cervista HPV HR were 91.4% vs. 84.5% and 73.4%, vs. 72.7%, respectively, when those higher than low-grade squamous intraepithelial lesions were regarded as abnormalities. HPV genotyping for HPV 16/18 detected cervical intraepithelial neoplasias (CINs) better than HR HPV tests (66.7% vs. 24.6% by HPV4A ACE, 52.6% vs. 25.9% by Cervista HPV assays in CIN II or more, relatively). Conclusion: Seeplex HPV4A ACE is an effective method as the PCR and the Cervista HPV assays for the detection of HR HPVs and for genotyping of HPV 16 and 18.

Original languageEnglish
Pages (from-to)5-10
Number of pages6
JournalJournal of Gynecologic Oncology
Volume23
Issue number1
DOIs
Publication statusPublished - 2012 Mar 5

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Polymerase Chain Reaction
Cervical Intraepithelial Neoplasia
ROC Curve
Cell Biology
Genotype
Sensitivity and Specificity
Squamous Intraepithelial Lesions of the Cervix

Keywords

  • Cervista HPV 16/18
  • Cervista HPV HR
  • High-risk HPV
  • HPV 16
  • HPV 18
  • Seeplex HPV4A ACE

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

@article{c47b327b48bb48a6a36b28ed7040a693,
title = "Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media",
abstract = "Objective: To validate the efficacy of Seeplex HPV4A ACE for the detection of high-risk (HR) human papillomavirus (HPV) and HPV 16 and/or HPV 18 genotypes as compared to the PCR method and the Cervista HPV assays in cervical swab samples. Methods: Besides liquid-based cytology, additional 97 cervical swab samples were collected for HPV genotyping by HPV4A ACE, Cervista HPV assays, and PCR method. To check the statistical differences, we also conducted the paired proportion test, Cohen' s κ statistic, and a receiver operating characteristic curve. Results: Seeplex HPV4A ACE and the Cervista HPV HR showed substantial agreement with PCR for detection of HR HPVs (88.3{\%}, κ=0.767 and 81.7{\%}, κ=0.636, respectively). Seeplex HPV4A ACE also showed substantial agreement with the Cervista HPV 16/18 test (89.5{\%}, κ=0.628). Additionally, the sensitivity and specificity of Seeplex HPV4A ACE and Cervista HPV HR were 91.4{\%} vs. 84.5{\%} and 73.4{\%}, vs. 72.7{\%}, respectively, when those higher than low-grade squamous intraepithelial lesions were regarded as abnormalities. HPV genotyping for HPV 16/18 detected cervical intraepithelial neoplasias (CINs) better than HR HPV tests (66.7{\%} vs. 24.6{\%} by HPV4A ACE, 52.6{\%} vs. 25.9{\%} by Cervista HPV assays in CIN II or more, relatively). Conclusion: Seeplex HPV4A ACE is an effective method as the PCR and the Cervista HPV assays for the detection of HR HPVs and for genotyping of HPV 16 and 18.",
keywords = "Cervista HPV 16/18, Cervista HPV HR, High-risk HPV, HPV 16, HPV 18, Seeplex HPV4A ACE",
author = "Min, {Kyung Jin} and So, {Kyeong A.} and Jieun Lee and Hong, {Hye Ri} and Jin-Hwa Hong and Lee, {Jae Kwan} and Aeree Kim",
year = "2012",
month = "3",
day = "5",
doi = "10.3802/jgo.2012.23.1.5",
language = "English",
volume = "23",
pages = "5--10",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "1",

}

TY - JOUR

T1 - Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media

AU - Min, Kyung Jin

AU - So, Kyeong A.

AU - Lee, Jieun

AU - Hong, Hye Ri

AU - Hong, Jin-Hwa

AU - Lee, Jae Kwan

AU - Kim, Aeree

PY - 2012/3/5

Y1 - 2012/3/5

N2 - Objective: To validate the efficacy of Seeplex HPV4A ACE for the detection of high-risk (HR) human papillomavirus (HPV) and HPV 16 and/or HPV 18 genotypes as compared to the PCR method and the Cervista HPV assays in cervical swab samples. Methods: Besides liquid-based cytology, additional 97 cervical swab samples were collected for HPV genotyping by HPV4A ACE, Cervista HPV assays, and PCR method. To check the statistical differences, we also conducted the paired proportion test, Cohen' s κ statistic, and a receiver operating characteristic curve. Results: Seeplex HPV4A ACE and the Cervista HPV HR showed substantial agreement with PCR for detection of HR HPVs (88.3%, κ=0.767 and 81.7%, κ=0.636, respectively). Seeplex HPV4A ACE also showed substantial agreement with the Cervista HPV 16/18 test (89.5%, κ=0.628). Additionally, the sensitivity and specificity of Seeplex HPV4A ACE and Cervista HPV HR were 91.4% vs. 84.5% and 73.4%, vs. 72.7%, respectively, when those higher than low-grade squamous intraepithelial lesions were regarded as abnormalities. HPV genotyping for HPV 16/18 detected cervical intraepithelial neoplasias (CINs) better than HR HPV tests (66.7% vs. 24.6% by HPV4A ACE, 52.6% vs. 25.9% by Cervista HPV assays in CIN II or more, relatively). Conclusion: Seeplex HPV4A ACE is an effective method as the PCR and the Cervista HPV assays for the detection of HR HPVs and for genotyping of HPV 16 and 18.

AB - Objective: To validate the efficacy of Seeplex HPV4A ACE for the detection of high-risk (HR) human papillomavirus (HPV) and HPV 16 and/or HPV 18 genotypes as compared to the PCR method and the Cervista HPV assays in cervical swab samples. Methods: Besides liquid-based cytology, additional 97 cervical swab samples were collected for HPV genotyping by HPV4A ACE, Cervista HPV assays, and PCR method. To check the statistical differences, we also conducted the paired proportion test, Cohen' s κ statistic, and a receiver operating characteristic curve. Results: Seeplex HPV4A ACE and the Cervista HPV HR showed substantial agreement with PCR for detection of HR HPVs (88.3%, κ=0.767 and 81.7%, κ=0.636, respectively). Seeplex HPV4A ACE also showed substantial agreement with the Cervista HPV 16/18 test (89.5%, κ=0.628). Additionally, the sensitivity and specificity of Seeplex HPV4A ACE and Cervista HPV HR were 91.4% vs. 84.5% and 73.4%, vs. 72.7%, respectively, when those higher than low-grade squamous intraepithelial lesions were regarded as abnormalities. HPV genotyping for HPV 16/18 detected cervical intraepithelial neoplasias (CINs) better than HR HPV tests (66.7% vs. 24.6% by HPV4A ACE, 52.6% vs. 25.9% by Cervista HPV assays in CIN II or more, relatively). Conclusion: Seeplex HPV4A ACE is an effective method as the PCR and the Cervista HPV assays for the detection of HR HPVs and for genotyping of HPV 16 and 18.

KW - Cervista HPV 16/18

KW - Cervista HPV HR

KW - High-risk HPV

KW - HPV 16

KW - HPV 18

KW - Seeplex HPV4A ACE

UR - http://www.scopus.com/inward/record.url?scp=84863263730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863263730&partnerID=8YFLogxK

U2 - 10.3802/jgo.2012.23.1.5

DO - 10.3802/jgo.2012.23.1.5

M3 - Article

VL - 23

SP - 5

EP - 10

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 1

ER -